Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Researchers have discovered that an enzyme can serve as an ideal target for developing new therapeutics against Lyme disease, and most likely other tick-borne diseases as well.

Researchers have discovered that an enzyme can serve as an ideal target for developing new therapeutics against Lyme disease, ...

Northwestern Medicine investigators have uncovered new insights into how intercellular "glue" functions to enable ...

Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and ...

Antibodies, which recognize viruses and proteins that the body has encountered before, have long gotten most of the credit ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

Olivier Negre Chief Scientific Officer Smart Immune In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

An Australian startup has unveiled the world’s first commercial biological computer that runs on living human brain cells. Melbourne-based Cortical Labs launched the CL1 at Mobile World Congress ...